Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cannabinoids in clinical practice.

E M Williamson1, F J Evans

  • 1Centre for Pharmacognosy, The School of Pharmacy, University of London, England.

Drugs
|January 11, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Social inequities impact infant mortality due to congenital heart disease.

Public health·2023
Same author

Effectiveness of scoliosis-specific exercises for adolescent idiopathic scoliosis compared with other non-surgical interventions: a systematic review and meta-analysis.

Physiotherapy·2019
Same author

Production of phytosterols by mature Digitalis purpurea L. plants.

Planta·2014
Same author

Uptake of [2-(14)C] mevalonic acid by lipid and glycoside sterols.

Planta·2014
Same author

Managing Injuries of the Neck Trial (MINT): a randomised controlled trial of treatments for whiplash injuries.

Health technology assessment (Winchester, England)·2012
Same author

Comparison of the antidiabetic activity of Berberis lyceum root extract and berberine in alloxan-induced diabetic rats.

Phytotherapy research : PTR·2008
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Cannabis and its compounds show therapeutic potential for pain, muscle spasms, and nausea. While tetrahydrocannabinol (THC) is psychoactive, other cannabinoids like cannabidiol (CBD) offer non-psychoactive benefits, suggesting standardized cannabis extracts may be clinically useful.

Area of Science:

  • Pharmacology
  • Neuroscience
  • Clinical Medicine

Background:

  • Cannabis contains various cannabinoids, including psychoactive tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabigerol (CBG).
  • Clinical applications of cannabis are often hindered by anecdotal evidence, necessitating rigorous scientific investigation.
  • Cannabinoids interact with specific receptors, though their precise mechanisms of action require further elucidation.

Purpose of the Study:

  • To review the clinical potential of cannabis and its constituents.
  • To explore the therapeutic applications of cannabinoids in various medical conditions.
  • To assess the efficacy and safety profile of cannabis-based treatments.

Main Methods:

  • Review of existing clinical studies on cannabis and cannabinoids.

Related Experiment Videos

  • Analysis of preclinical data from experimental models.
  • Examination of anecdotal reports and case studies.

    • Main Results:

    • Cannabinoids demonstrate efficacy in managing multiple sclerosis symptoms like muscle spasms and tremor.
    • Tetrahydrocannabinol (THC) shows analgesic properties, while CBD and CBG exhibit anti-inflammatory and analgesic effects.
    • Cannabis and its derivatives are effective against chemotherapy-induced nausea and vomiting.

    Conclusions:

    • Standardized cannabis extracts may offer broader therapeutic benefits than isolated compounds.
    • Non-psychoactive cannabinoids present opportunities for developing targeted therapies.
    • While generally safe, potential adverse effects and interactions necessitate careful consideration in clinical use.